查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1179872

2023-2030 年糖尿病神经性足溃疡的全球市场

Global Diabetic Neurotherapy Foot Ulcers Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

在预测期内（2023 年至 2030 年），糖尿病神经性足溃疡市场规模预计将以 8.4% 的复合年增长率增长。

糖尿病性溃疡是导致截肢的最常见腿部损伤。 全科医生在早期发现和预防糖尿病足病方面发挥着至关重要的作用。 糖尿病足的管理需要深入了解主要的截肢危险因素、常规评估和细緻的预防性维护。 最常见的溃疡风险因素包括外周动脉闭塞性疾病、足部结构畸形和糖尿病性神经病变。

市场动态

推动全球糖尿病足溃疡市场的主要因素是糖尿病足溃疡增加导致的市场扩张、治疗技术进步引起的市场牵引以及特定类型足溃疡的可用性。有一定的敷料。

由于糖尿病足溃疡的增加，扩张正在加速。

糖尿病患者很容易患上糖尿病足溃疡，这可能导致足部截肢。 接受胰岛素治疗的糖尿病患者更容易患足部溃疡。 患有糖尿病、肥胖症以及肾臟、眼睛和心臟问题的人也可能患上糖尿病足溃疡。 烟草和酒精的使用都被认为会增加患病的风险。

据美国国立卫生研究院估计，全球每年有 9.1 至 2610 万糖尿病足溃疡发生。 据估计，15-25% 的糖尿病患者一生中会患上糖尿病足溃疡。 随着每年有越来越多的人被诊断出患有糖尿病，糖尿病足溃疡的患病率将不可避免地增加。 糖尿病足溃疡可发生于任何年龄，但最常见于 45 岁以上的糖尿病患者。 大多数患有足部溃疡的美国人是拉丁裔、非裔美国人和美洲原住民。 因此，糖尿病足溃疡发病率的增加会加速生长。

成本密集型伤口护理产品和糖尿病神经性足溃疡 (DME) 治疗预计会阻碍市场增长。

糖尿病足溃疡是糖尿病最常见的症状，也是导致死亡的主要原因。 随着细胞外蛋白、治疗剂和其他选择变得过于昂贵，替代疗法的技术发展不断加快预计将减缓市场增长。

COVID-19 影响分析

自 2019 年 12 月爆发 COVID-19 病毒以来，该病毒已传播到超过 75 个国家，世界卫生组织已宣布进入公共卫生紧急状态。 例如 例如，根据世界卫生组织的一项研究，截至 2021 年 7 月，全球约有 1.9 亿人感染了冠状病毒 (COVID-19)。

COVID-19 主要通过三种方式影响经济：直接改变供需、扰乱分销网络以及对企业和金融市场产生经济影响。 包括中国、印度、沙特阿拉伯、阿拉伯联合酋长国和埃及在内的许多国家普遍实行封锁，这使得将药品从一个地方转移到另一个地方变得困难重重。 此外，COVID-19大流行在各个方面对全球糖尿病足溃疡治疗市场的行业参与者构成了主要障碍。 获得製造药物製剂所需的原材料是运输不规范造成的主要问题之一。 随着患有 COVID-19 和其他危及生命的疾病的患者人数增加，分销商也发现商店对其产品的需求不稳定。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 由于糖尿病足溃疡的增加，扩张加速
      • 治疗技术进步推动市场
    • 约束因素
      • 昂贵的高级伤口护理产品和疗法限制了市场增长
    • 商机
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 定价分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按溃疡类型

  • 神经性溃疡
  • 缺血性溃疡
  • 神经缺血性溃疡

第八章治疗

  • 伤口敷料保护器
  • 生物製品
  • 其他

第 9 章最终用户

  • 医院
  • 专科诊所
  • 长期护理中心
  • 门诊手术中心
  • 家庭护理

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第11章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准
  • 值得关注的主要公司名单

第12章公司简介

  • Medtronic
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Organogenesis, Inc
  • Acelity L.P., Inc
  • B Braun Melsungen AG
  • Coloplast Corp
  • Medline Industries, Inc
  • 3M Healthcare
  • Molnlycke Health Care AB
  • Hyper oil
  • Smith & Nephew Plc.

第 13 章糖尿病神经性足部溃疡的全球市场-DataM

简介目录
Product Code: DMPH28

Market Overview

Diabetic Neuropathic Foot Ulcers Market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 8.4% during the forecast period (2023-2030).

The most frequent foot wounds resulting in lower extremity amputation are diabetic ulcers. General practitioners are crucial in the early detection or prevention of diabetic foot problems. The management of the diabetic foot necessitates in-depth familiarity with the primary amputation risk factors, routine evaluation, and meticulous preventive maintenance. The most frequent ulcer-forming risk factors include peripheral artery occlusive disease, structural foot deformity, and diabetic neuropathy.

Market Dynamics

The major factors driving the global diabetic neurotherapy foot ulcers market are the expansion is accelerated by the increasing number of diabetic foot ulcers, the market will be driven by treatment technology advancement and there are specific dressings available for a particular type of foot ulcer.

The expansion is accelerated by the increasing number of diabetic foot ulcers.

Patients with diabetes are prone to developing diabetic foot ulcers, which can necessitate the amputation of the leg. Patients with diabetes who use insulin to control their condition are more likely to develop a foot ulcer. In addition to diabetes, individuals with obesity, kidney, eye, and heart issues may also develop diabetic foot ulcers. Use of tobacco and alcohol both raises the risk of the illness.

According to the National Institutes of Health (U.S.A.), between 9.1 and 26.1 million diabetic foot ulcers occur annually over the world. In their lifetime, 15 to 25% of people with diabetes mellitus will get a diabetic foot ulcer. The prevalence of diabetic foot ulcers will inevitably rise as more people are diagnosed with diabetes each year. Although diabetic foot ulcers can develop at any age, they are most common in those with diabetes mellitus who are over 45. The majority of Americans with foot ulcers are Latinos, African Americans, and Native Americans. Thus, the growth is sped up by an increase in the incidence of diabetic foot ulcers.

Costly advanced wound care products and therapies of diabetic neurotherapy foot ulcers (DME) is expected to hamper the market's growth.

A diabetic foot ulcer is the most prevalent consequence of diabetes and a substantial cause of death. It is anticipated that ongoing technical developments in therapeutic alternatives will slow the market's growth because extracellular proteins, therapeutic agents, and other options have become too expensive.

COVID-19 Impact Analysis

The virus has spread to over 75 countries since the COVID-19 viral outbreak in December 2019, and the World Health Organization declared it a public health emergency. For instance, as of July 2021, about 190 million people worldwide were infected due to the coronavirus (COVID-19) manifestation, according to a study from the World Health Organization.

Three main ways that COVID-19 can affect the economy are directly altering supply and demand, disrupting distribution networks, and having an economic impact on businesses and financial markets. Many nations, including China, India, Saudi Arabia, the United Arab Emirates, Egypt, and others, have difficulty moving pharmaceuticals from one location to another due to widespread lockdowns. Furthermore, the COVID-19 pandemic poses significant obstacles for industry participants in the worldwide diabetic foot ulcer therapy market on numerous fronts. The availability of raw materials required to make pharmaceutical formulations is one of the major problems caused by transportation irregularities. Additionally, because of a rise in patients with COVID-19 and other life-threatening illnesses, distributors see irregular demand for their products from stores.

Segment Analysis

The wound care dressing diabetic Neurotherapy foot ulcers-type segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The advanced wound dressings segment dominated the market for treating diabetic foot ulcers worldwide. There are many kinds of hydrogel dressings for wound treatment, including alginate dressings, hydro fiber dressings, surgical dressings, and others. Foam dressings are the most popular type of wound care treatment nowadays. Patients who have non-healing wounds can benefit from advanced wound care dressings. It is an active non-woven wound dressing made entirely of natural biopolymer. The 360-degree, dynamic mode of action of wound care dressings allows for efficient discharge control, pain reduction, infection control, active wound healing, and scar improvement. The excellent absorption capacity and painless removal of wound care dressings enhance patient comfort. As a result, they are widely employed for the care of wounds in various phases, and key players are also releasing new products, which boosts the market for this category.

For instance, in October 2022, A new line of wound dressings named Theruptor Novo was introduced by Bengaluru-based Healthium Medtech for treating chronic wounds, including leg and foot ulcers caused by diabetes. With the introduction of Theruptor Novo, Healthium expands the range of proprietary solutions it already offers in the market for advanced wound dressings.

For instance, in September 2021, The American Company Human Biosciences (HBS) hinted that it would soon launch two wound care products in the Indian market. The two items have the names "Medifil" and "Skin Temp, according to an announcement from the company. The company plans to offer two of its wound care management products, "Medifil" and "Skin Temp" in India soon.

Geographical Analysis

North America holds the largest market share in the global diabetic neurotherapy foot ulcers market.

The most prevalent illness in this age range is diabetes, which frequently results in diabetic foot ulcers. The prevalence of diabetic foot ulcers has increased due to people living more sedentary lifestyles. In this region, diabetes affects one in two people, which has helped to increase the demand for diabetic foot ulcer treatments. The International Diabetes Federation 2021 estimates that 51 million people in North America and the Caribbean now have diabetes. More than 20 million Americans are thought to experience peripheral neuropathy. However, given that not everyone who displays neuropathy symptoms is tested for the condition and that tests are currently not developed to detect all forms of neuropathy, this number may be much higher.

Major market competitors, rising healthcare GDP spending, and enhanced reimbursement for DFU therapy primarily influence the region's market growth. According to the Canadian Diabetes Association 2020, diabetes accounts for 70% of lower limb amputations carried out in hospitals and are the most common reason for non-traumatic lower limb amputation in Canadian adults. Canadian individuals with diabetes are nearly 20 times more likely than the general population to have non-traumatic lower limb amputations, 85% of which are preceded by a foot ulcer.

Competitive Landscape

The diabetic neurotherapy foot ulcers market is moderately competitive with local and global companies' presence Medtronic, Organogenesis, Inc, Acelity L.P., Inc, B Braun Melsungen AG, Coloplast Corp, Smith & Nephew Plc, Medline Industries, Inc, 3M Healthcare, Molnlycke Health Care AB, Hyper oil and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in June 2022, Smith + Nephew will spend over $100 million to build a top-notch research and development, manufacturing, and flexible office building. A funding from the UK government will also help to fund the development. In its first ten years of operation, the new factory is anticipated to support sales of more than $10 billion.

Hyper Oil.

Overview: The product's patent license was obtained by RI.MOS in 2005, and clinical trials for the treatment of ulcers and bedsores in humans commenced in 2006. Even the most hopeful predictions were surpassed by the initial results of the Clinica Barbantini of Lucca, Tuscany, one of the most significant National reference centers, conducted by the Department of Vulnology. Holoil (a brand for the Italian market) and Hyperoil (a brand for international markets) received CE approval as Class IIb Medical Devices in 2008. In 2009, RI.MOS launched the Hypermix for Veterinary Use and Holoil for Human Use brands to promote the product in the Italian market (in 2011).

Product Portfolio:

Fast Healing Advanced Wound Dressing: Infection prevention, re-epithelialization support, fibrinolytic action, and other benefits are provided by hyperoil. At all stages of tissue repair, it only needs the assistance of secondary dressings to protect and/or absorb, as necessary, while carrying out all other essential tasks on its own.

The global diabetic neurotherapy foot ulcers market report would provide access to approx.: 45 + market data table, 40 + figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The expansion is accelerated by the increasing number of diabetic foot ulcers
      • 4.1.1.2. The market will be driven by treatment technology advancement
    • 4.1.2. Restraints:
      • 4.1.2.1. Costly advanced wound care products and therapies restrain market expansion
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Ulcer Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 7.1.2. Market Attractiveness Index, By Ulcer Type
  • 7.2. Neuropathic Ulcers
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Ischemic Ulcers
  • 7.4. Neuro-Ischemic Ulcers

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type
  • 8.2. Wound Care Dressings
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Biologics
  • 8.4. Others

9. By End user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 9.1.2. Market Attractiveness Index, By End user
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Specialty Clinics
  • 9.4. Long term Care Centres
  • 9.5. Ambulatory Surgical Centres
  • 9.6. Home Care setting

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size AnalysisUS$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Products Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Medtronic
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Organogenesis, Inc
  • 12.3. Acelity L.P., Inc
  • 12.4. B Braun Melsungen AG
  • 12.5. Coloplast Corp
  • 12.6. Medline Industries, Inc
  • 12.7. 3M Healthcare
  • 12.8. Molnlycke Health Care AB
  • 12.9. Hyper oil
  • 12.10. Smith & Nephew Plc.

LIST NOT EXHAUSTIVE

13. Global Diabetic Neurotherapy Foot Ulcers Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Application
  • 13.3. Contact Us